Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00195286
Collaborator
(none)
180
27
37
6.7
0.2
Study Details
Study Description
Brief Summary
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Observational
Actual Enrollment
:
180 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
Study Start Date
:
Jun 1, 2004
Actual Primary Completion Date
:
Jul 1, 2007
Actual Study Completion Date
:
Jul 1, 2007
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
16 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.
Exclusion Criteria:
-
Patients known, or thought to be hypersensitivity to beta-lactams
-
Patients with an uncomplicated urinary tract infection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Antequera (Málaga) | Spain | |||
| 2 | Avila | Spain | |||
| 3 | Barcelona | Spain | |||
| 4 | Berga (Barcelona) | Spain | |||
| 5 | Caceres | Spain | |||
| 6 | Castellón | Spain | |||
| 7 | Ciudad Real | Spain | |||
| 8 | Cuenca | Spain | |||
| 9 | Cádiz | Spain | |||
| 10 | Ferrol | Spain | |||
| 11 | Granada | Spain | |||
| 12 | Jaen | Spain | |||
| 13 | Las Palmas | Spain | |||
| 14 | Lorca (Murcia) | Spain | |||
| 15 | Lugo | Spain | |||
| 16 | Lérida | Spain | |||
| 17 | Madrid | Spain | |||
| 18 | Osuna (Sevilla) | Spain | |||
| 19 | Palma Mallorca | Spain | |||
| 20 | Pamplona | Spain | |||
| 21 | Pontevedra | Spain | |||
| 22 | Terrasa | Spain | |||
| 23 | Torrelavega | Spain | |||
| 24 | Valencia | Spain | |||
| 25 | Valladolid | Spain | |||
| 26 | Vitoria | Spain | |||
| 27 | Zaragoza | Spain |
Sponsors and Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
- Study Director: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00195286
Other Study ID Numbers:
- 101315
First Posted:
Sep 19, 2005
Last Update Posted:
Sep 25, 2009
Last Verified:
Sep 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: